evidencegaps
Primary study · included by 1 review

The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ).

Miranda 2021 · Miranda Michele, Gianfreda Francesco, Raffone Carlo, et al. · BioMed research international · 2021

Included by

Antibiotic Prophylaxis and Postoperative Therapy in Tooth Extractions for Patients at Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Scoping Review.
Non-Cochrane · intervention · 2025 · cited as Miranda 2021 · Table 1; reference 29; Figure 4
Outcome this study informsPooled effectEvidenceCertainty
MRONJ incidence (MRONJ/bone exposure cases)
High-dose bone-modifying agent therapy vs Low-dose bone-modifying agent therapy
OR 3.26 [1.74, 6.10]16 studies · 1187 participantsGRADE not reported
MRONJ incidence (MRONJ/bone exposure cases)
High-dose bone-modifying agent therapy vs Low-dose bone-modifying agent therapy
OR 33.5 [6.3, 177.8]32 studiesGRADE not reported
MRONJ incidence (MRONJ/bone exposure cases)
High-dose bone-modifying agent therapy vs Low-dose bone-modifying agent therapy
OR 2.82 [1.46, 5.43]16 studies · 1187 participantsGRADE not reported

1 including review in total.